Publications 2002
Dipeptidylpeptidase IV inhibitors downregulate NHE3 activity in OKP cells.
Girardi, A.C.C.; Knauf, F.; Demuth, H.-U.; Aronson, P.S.
J. Am. Soc. Nephrol. 2002, 13, 477A.
Rebuttal to Deacon and Holst: “Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1” Versus “Dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective”
Demuth, H.-U.; Hinke, S.A.; Pederson, R.A.; McIntosh, C.H.S.
Biochem. Biophys. Res. Commun. 2002, 296 (2), 229-232.
Modulation of Inositol (1,4,5) Triphoshate Concentration by Prolyl Endopeptidase Inhibition
Schulz, I.; Neubauer, A.; Holloschi, A.; Heiser, U.; Hafner, M.; Demuth, H.-U.; Gerhartz, B.
Eur. J. Biochemistry 2002, 269, 5813-5820.
Long-term Dipeptidyl-Peptidase IV Inhibitor Treatment Improves Hepatic and Peripheral Insulin Sensitivity in the VDF Zucker Rat: A Euglycemic-Hyperinsulinemic Clamp Study
Pospisilik, A.; Stafford, S.G.; Demuth, H.-U.; McIntosh, C.H.S.; Pederson, R.A.
Diabetes 2002, 51(9), 2677-2683.
Heterologous Expression and Characterization of human Glutaminyl Cyclase:
Evidence for a Disulfide Bond with Importance for the catalytic active structure.
Schilling, S.; Hoffmann, T.; Rosche, F.; Manhart, S.; Wasternack, C.; Demuth, H.-U.
Biochemistry 2002, 41, 10849-10857.
Inhibition of mammalian legumain by Michael acceptors and AzaAsn-halomethylketones
Niestroj, A.; Feußner, K.; Heiser, U.; Dando, P. M.; Barett, A.; Gerhartz, B.; Demuth, H.-U.
Biological Chemistry 2002, 383 (7-8) 1205-1214.
Effect of neuropeptide Y (NPY) on inflammatory paw edema in the rat: involvement
of peripheral NPY Y1 and Y5 receptors and interaction with dipeptidyl-peptidase IV (CD26)
Dimitrijevic, M.; Stanojevic, St.; Vujic, V.; Evic-Jovanovic, V.-K.; Beck-Sickinger, A.; Demuth, H.-U.; von Hörsten, S.
Journal of Neuroimmunology 2002, 129(1-2) 35-42.
CD26/DP IV in Stress-induced, Cytokine-mediated Abortions
Hildebrandt, M.; Demuth, H.-U.; Reutter, W.
Ectopeptidases: CD13/Aminopeptidase N and CD26/Dipeptidylpeptidase IV in Medicine and Biology. J. Langner and S. Ansorge, eds., Kluwer Academic Plenum Press, New York, 2002.
Therapeutic Strategies Exploiting DP IV inhibition – Target Disease: Type 2 Diabetes
Hoffmann, T.; Demuth, H.-U.
Ectopeptidases: CD13/Aminopeptidase N and CD26/Dipeptidylpeptidase IV in Medicine and Biology. J. Langner and S. Ansorge, eds., Kluwer Academic Plenum Press, New York, 2002.
Enzyme classes and mechanisms
Gerhartz, B.; Niestroj, A.J.; Demuth, H.-U.
Proteinase and Peptidase Inhibition. Recent Potential Targets For Drug Development.
H.J. Smith and C. Simons, eds., Taylor & Francis, London and New York, 2002.
Investigation of metformin effects on dipeptidylpeptidase IV (DP IV) degradation of glucagon-like peptide (GLP-1)
Hinke, S.A.; Kühn-Wache, K.; Hoffmann, T.; Pederson, R.A.; McIntosh, C.H.S.; Demuth, H.-U.
Biochem Biophys Res Commun 2002, 291 (5) 1302-1308.
Dipeptidyl Peptidase IV-Resistant [D-Ala2]Glucose-dependent Insulinotropic Polypeptide (GIP) Improves Glucose Tolerance in Normal and Obese Diabetic Rats
Hinke, S.A.; Gelling, R.W.; Pederson, R.A.; Manhart, S.; Nian, C.; Demuth, H.-U.; McIntosh, C.H.S.
Diabetes 2002, 51 (3) 652-661.
Long-term treatment with the DP IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia and b-cell glucose responsiveness in VDF (fa/fa) Zucker Rats
Pospisilik, J.A.; Stafford, S.G.; Demuth, H.-U.; Brownsey, R.; Parkhouse, W.; Finegood, D.T.; McIntosh, C.H.S.; Pederson, R.A.
Diabetes 2002, 51 (4) 943-950.
Continuous Spectrometric Assays for Glutaminyl Cyclase Activity
Schilling, S.; Hoffmann, T.; Jaschinsky, B.; Wermann, M.; Heiser, U.; Wasternack, C.; Demuth, H.-U.
Analytical Biochemistry 2002, 303 (1) 49-56